CSL Behring seeks proposals for Interlaken Leadership Awards, supporting innovative research into neuroimmunology
Proposals for global grant programme may be submitted at www.InterlakenLeadershipAwards.com
UK — 01.11.2011
CSL Behring has announced it is seeking proposals for the next round of Interlaken Leadership Awards as part of its continued commitment to innovative immunoglobulin (Ig) research. Established in 2010, this annual global awards programme provides monetary grants and/or product supply to advance medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurological disorders.
From the management of primary immunodeficiency to the control of autoimmune and inflammatory conditions, Ig therapy has a wide range of indications. The Interlaken Leadership Awards programme was created to help identify new clinical
applications for polyvalent immunoglobulins for potential further clinical investigation. The ultimate aim is to have a positive impact on the quality of life for people who are diagnosed with a wide range of neurological conditions such as multifocal motor neuropathy, myasthenia gravis and chronic pain.
“The number of potential clinical applications for immunoglobulin therapy continues to expand and recent research has identified several novel and promising uses that may be able to help people with debilitating and degenerative neurological conditions,” said Jeffrey Baggish, M.D., Director of Medical Affairs, Immunology & Pulmonary at CSL Behring. “The Interlaken Leadership Awards further underpins CSL Behring’s position at the forefront of immunoglobulin research by supporting investigators who are devoted to improving patient outcomes by advancing the evolving science behind Ig therapy.”
Proposal Submission Process
Any individual actively engaged in clinical or basic research in a field of study consistent with the goals of the Interlaken Leadership Awards program is eligible.
For more information, please visit:
www.InterlakenLeadershipAwards.com
.
The deadline for submissions is 21 December 2011.
About the International Immunoglobulin Symposium in Interlaken
For more than three decades, CSL Behring has sponsored a high-level scientific symposium in Interlaken, Switzerland. First held in 1981, and most recently in 2009, the International Immunoglobulin Symposium focuses exclusively on scientific and clinical research in the field of polyvalent immunoglobulins. Research presented at the Interlaken symposium is consistently at the forefront of immunoglobulin research. Since its inception, the International Immunoglobulin Symposium has won the respect and support of top international scientists and clinicians from many different fields of research. For more information, please visit:
hhttp://www.interlakenleadershipawards.com/symposium.aspx.
About CSL Behring
CSL Behring is a global leader in the plasma protein therapeutics industry. Passionate about improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant products and related services. CSL Behring therapies are used in the treatment of rare diseases such as immune deficiency disorders, hereditary angioedema, haemophilia, von Willebrand disease and other bleeding disorders. Other products are used for the prevention of haemolytic diseases in the newborn. The company also operates one of the world’s largest plasma collection networks,
CSL Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit
www.cslbehring.co.uk.
For further information:
Rebecca Turner, Communications & E-business Executive
CSL Behring UK Ltd
01444 447 429
Send an email